Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

LM 103

Next Previous
X
Search
Drug Profile

LM 103

Alternative Names: Autologous tumour infiltrating lymphocytes - Suzhou BlueHorse Therapeutics; LM-103

Latest Information Update: 04 Aug 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Suzhou BlueHorse Therapeutics
  • Class Antineoplastics; Immunotherapies; T lymphocyte cell therapies; Tumour infiltrating lymphocyte therapies
  • Mechanism of Action Immunologic cytotoxicity; Lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 25 Jul 2023 Suzhou BlueHorse Therapeutics plans a phase 0 trial for Solid tumours (Late-stage disease, Second-line therapy or greater) in August 2023 (IV, Infusion) (NCT05971576)
  • 19 May 2023 Suzhou BlueHorse Therapeutics initiates a phase 0 trial for Solid tumors (Late-stage disase) in China (IV, Infusion)(NCT05941936)
  • 30 May 2022 Phase-I clinical trials in Solid tumours (Late-stage disease) in China (IV) (NCT05366478)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top